Eloxx Pharmaceuticals (ELOX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$4.5M

Net income growth (year over year)

−138.08%

Net margin

—

Return on equity

—

EPS (trailing twelve months)

$3.57

Book value per share

$11.50

P/E (trailing twelve months)

—

Price to book

1.06

Debt to assets

26.77%

Payout ratio

—

Dividend yield

—

Company profile

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

• How do I buy stock in Eloxx Pharmaceuticals (ELOX)?

  ELOX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.